LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Bought by Congress Wealth Management LLC DE

Congress Wealth Management LLC DE lifted its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 3.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 114,088 shares of the medical instruments supplier’s stock after buying an additional 4,279 shares during the period. Congress Wealth Management LLC DE owned approximately 0.51% of LeMaitre Vascular worth $10,512,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in LMAT. New York State Teachers Retirement System lifted its position in LeMaitre Vascular by 1.2% during the 4th quarter. New York State Teachers Retirement System now owns 8,189 shares of the medical instruments supplier’s stock worth $755,000 after acquiring an additional 100 shares during the period. Flputnam Investment Management Co. raised its stake in shares of LeMaitre Vascular by 3.6% during the fourth quarter. Flputnam Investment Management Co. now owns 2,923 shares of the medical instruments supplier’s stock worth $269,000 after purchasing an additional 102 shares during the last quarter. Norden Group LLC lifted its holdings in shares of LeMaitre Vascular by 4.5% during the fourth quarter. Norden Group LLC now owns 2,371 shares of the medical instruments supplier’s stock worth $218,000 after purchasing an additional 103 shares during the period. Blue Barn Wealth LLC lifted its holdings in shares of LeMaitre Vascular by 4.4% during the fourth quarter. Blue Barn Wealth LLC now owns 2,485 shares of the medical instruments supplier’s stock worth $229,000 after purchasing an additional 104 shares during the period. Finally, Shaker Investments LLC OH grew its position in LeMaitre Vascular by 0.8% in the 4th quarter. Shaker Investments LLC OH now owns 13,948 shares of the medical instruments supplier’s stock valued at $1,285,000 after buying an additional 112 shares during the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on LMAT. Lake Street Capital upped their price objective on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the stock a “buy” rating in a research report on Friday, February 28th. Oppenheimer downgraded shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Friday, February 28th. StockNews.com cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Barrington Research downgraded LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Friday, February 28th. Finally, Wells Fargo & Company started coverage on LeMaitre Vascular in a research note on Thursday, February 13th. They issued an “equal weight” rating and a $95.00 price target on the stock. Five equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $95.25.

LeMaitre Vascular Price Performance

NASDAQ LMAT opened at $86.07 on Tuesday. The business has a 50 day moving average price of $94.15 and a 200 day moving average price of $94.50. The company has a market capitalization of $1.94 billion, a P/E ratio of 47.03, a PEG ratio of 2.22 and a beta of 0.89. LeMaitre Vascular, Inc. has a 1-year low of $62.39 and a 1-year high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.49. The firm had revenue of $55.81 million during the quarter, compared to the consensus estimate of $55.99 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. On average, research analysts expect that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 27th. Investors of record on Thursday, March 13th will be given a dividend of $0.20 per share. The ex-dividend date is Thursday, March 13th. This represents a $0.80 dividend on an annualized basis and a yield of 0.93%. This is a positive change from LeMaitre Vascular’s previous quarterly dividend of $0.16. LeMaitre Vascular’s dividend payout ratio (DPR) is 41.24%.

Insiders Place Their Bets

In related news, insider Trent G. Kamke sold 2,009 shares of the firm’s stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total value of $164,979.08. Following the sale, the insider now directly owns 5,564 shares of the company’s stock, valued at approximately $456,915.68. This trade represents a 26.53 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 10.79% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.